Welcome to our dedicated page for Neumora Therapeutics news (Ticker: NMRA), a resource for investors and traders seeking the latest updates and insights on Neumora Therapeutics stock.
Neumora Therapeutics Inc (NMRA) is a clinical-stage biopharmaceutical company advancing novel treatments for brain diseases through precision neuroscience. This page serves as the definitive source for NMRA-related news, offering investors and stakeholders timely updates on clinical developments, regulatory milestones, and strategic initiatives.
Access curated press releases and analysis covering key aspects of Neumora's operations, including progress reports on its depression therapy navacaprant (KOR antagonist), Alzheimer's agitation candidate NMRA-511 (V1aR antagonist), and preclinical M4 PAM programs. Our repository simplifies tracking of trial phases, partnership announcements, and scientific publications.
All content undergoes rigorous verification to ensure alignment with financial disclosure standards. Bookmark this page for efficient monitoring of NMRA's innovative work in neuropsychiatric and neurodegenerative disorder treatments. Check regularly for updates on pipeline advancements and corporate announcements that may impact research trajectories.
Neumora Therapeutics has initiated a Phase 1b study evaluating NMRA-511 for treating agitation in Alzheimer's disease (AD). NMRA-511, an oral antagonist of the vasopressin 1a receptor (V1aR), was well-tolerated in prior studies with no serious adverse events. The Phase 1b study, starting with healthy elderly adults and then AD patients, aims to assess safety, tolerability, and efficacy. The study will measure changes in agitation using the Cohen-Mansfield Agitation Inventory. Neumora expects to report topline data in the second half of 2025.
Neumora Therapeutics has initiated a Phase 2 clinical trial for navacaprant, targeting bipolar depression. The company aims to evaluate the safety and efficacy of the 80 mg oral KOR antagonist, which previously showed promise in treating major depressive disorder (MDD). The trial will involve 60 patients and focus on improvements in depressive symptoms and anhedonia, with results expected in the second half of 2025. Additionally, navacaprant is in Phase 3 development for MDD, with data from the KOASTAL-1 study anticipated in Q4 2024. This study could lead to broader applications for navacaprant in bipolar disorder.
Neumora Therapeutics, Inc. (Nasdaq: NMRA) reported strong financial results for Q1 2024 with $423.0 million in cash, guidance narrowed to Q4 2024 for Phase 3 data from KOASTAL-1 study with navacaprant in MDD, and multiple upcoming clinical study initiations. The company is well-positioned with a robust pipeline targeting neuropsychiatric and neurodegenerative diseases.
Neumora Therapeutics, Inc. (Nasdaq: NMRA) will participate in two investor conferences in May: BofA Securities Healthcare Conference 2024 and RBC Capital Markets Global Healthcare Conference. The company's therapeutic pipeline includes seven clinical and pre-clinical brain disease programs.
FAQ
What is the current stock price of Neumora Therapeutics (NMRA)?
What is the market cap of Neumora Therapeutics (NMRA)?
